Explore › Finding
Finding null
Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases among dolutegravir-exposed pregnancies in MarketScan and only one NTD case among dolutegravir-exposed pregnancies in Medicaid.
Effect sizeNTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)
ComparatorWomen without HIV (NTD rate 4.1 per 10000 in MarketScan, 5.7 per 10000 in Medicaid)
Effect summarynull; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Connected entities

Interventions
dolutegravir exposure
Conditions
HIV
Outcomes
Increase or decrease in folic acid content of the diet. Prevention of megaloblastic anemia and risk of neural tube defects in the newborn. (Source: Office of Dietary Supplments National Institutes of Health. Dietary Supplement Fact Sheet: Folate)
Populations
Pregnant Women

Source

PMC10614030
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study
Read on PMC → · View in graph →